Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation

• Published in: ACS medicinal chemistry letters Vol. 2; no. 10; pp. 780 - 785
• Main Authors: Khan, Pasha M, Correa, Ricardo G, Divlianska, Daniela B, Peddibhotla, Satyamaheshwar, Sessions, E. Hampton, Magnuson, Gavin, Brown, Brock, Suyama, Eigo, Yuan, Hongbin, Mangravita-Novo, Arianna, Vicchiarelli, Michael, Su, Ying, Vasile, Stefan, Smith, Layton H, Diaz, Paul W, Reed, John C, Roth, Gregory P
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13.10.2011
• Subjects: Letter; NF-κB activation; 2-aminobenzimidazole; NOD1; MLPCN; hit-to-probe; ML130
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/ml200158b

NOD1 (nucleotide-binding oligomerization domain 1) protein is a member of the NLR (NACHT and leucine rich repeat domain containing proteins) protein family, which plays a key role in innate immunity as a sensor of specific microbial components derived from bacterial peptidoglycans and induction of inflammatory responses. Mutations in NOD proteins have been associated with various inflammatory diseases that affect NF-κB (nuclear factor κB) activity, a major signaling pathway involved in apoptosis, inflammation, and immune response. A luciferase-based reporter gene assay was utilized in a high-throughput screening program conducted under the NIH-sponsored Molecular Libraries Probe Production Center Network program to identify the active scaffolds. Herein, we report the chemical synthesis, structure–activity relationship studies, downstream counterscreens, secondary assay data, and pharmacological profiling of the 2-aminobenzimidazole lead (compound 1c, ML130) as a potent and selective inhibitor of NOD1-induced NF-κB activation.